Abstract:Background We have reported that the RNA N6-methyladenosine (m6A) reader YTHDF1 plays an important role in the tumourigenesis of intrahepatic cholangiocarcinoma (ICC). However, whether YTHDF1 influences the tumour immune microenvironment (TIME) of ICC remains unknown. Here, we investigated the function and mechanism by which YTHDF1 regulates the TIME of ICC. Methods Different mouse models, including the ICC orthotopic mouse model, ICC hydrodynamic injection mouse model, and liver-specific Ythdf1-overexpressing mice, were applied. Tumour-infiltrating immune cells were profiled with flow cytometry and immunohistochemistry staining. The clinical significance of YTHDF1 in ICC TIME was evaluated with immunostaining with human ICC tissue microarrays. Chemokine array and ELISA assays were used to identify the cytokines and chemokines regulated by YTHDF1. The downstream molecular targets of YTHDF1 were identified by integrating RNA-sequencing, MeRIP-sequencing, RNA immunoprecipitation-sequencing, and ribosome-profiling. Results Ythdf1-knockdown orthotopic ICC mouse model and Ythdf1-overexpressed ICC hydrodynamic injection mouse model elucidated that YTHDF1 recruited myeloid-derived suppressor cells (MDSCs) to tumours and inhibited the infiltration and cytotoxic function of CD8+ T cells, thus promoting tumour progression. Immunostaining of human ICC tissue microarray (n = 188) verified that higher expression of YTHDF1 was positively related to increased MDSCs accumulation (P < 0.001) and decreased CD8+ T cells infiltration (P < 0.001). Mechanistically, YTHDF1 upregulated CXCL6 expression in ICC, which recruited and activated MDSCs by binding to its receptor CXCR2, leading to the dysfunction of CD8+ T cells. By integrating multi-omics sequencing data, we pinpointed FOSL2, a transcription factor, as the key downstream target of YTHDF1. YTHDF1 bound to m6A-modified FOSL2 mRNA and promoted its translation. In turn, FOSL2 is directly bound to the CXCL6 promoter and facilitates CXCL6 transcription. The liver-specific Ythdf1-overexpressing mice model also confirmed that YTHDF1 upregulated the protein expression of FOSL2 and CXCL6. Furthermore, Ythdf1-knockdown synergized with anti-PD-L1 treatment significantly enhanced the therapeutic effects of immunotherapy in ICC. Conclusions YTHDF1 facilitates ICC immune escape via FOSL2-CXCL6-CXCR2 signaling, which recruits and activates MDSCs and induces cytotoxic CD8+ T-cell dysfunction. Targeting YTHDF1 may be a promising strategy for improving immunotherapy efficacy in ICC.

Tumor-intrinsic YTHDF1 drives immune evasion and resistance to immune checkpoint inhibitors via promoting MHC-I degradation

The Roles and Mechanisms of YTH Domain-Containing Proteins in Cancer Development and Progression.

The tumor-intrinsic role of the m 6 A reader YTHDF2 in regulating immune evasion

YTHDF2 upregulation and relocation dictate CD8 T cell polyfunctionality in tumor immunity

YTHDF2 Upregulation and Subcellular Localization Dictate CD8 T Cell Polyfunctionality in Anti-Tumor Immunity

YTHDF1 Shapes "cold" Tumor and Inhibits CD8+ T Cells Infiltration and Function in Breast Cancer.

YTH domain family protein 3 accelerates non-small cell lung cancer immune evasion through targeting CD8+ T lymphocytes

YTHDF1's Regulatory Involvement in Breast Cancer Prognosis, Immunity, and the ceRNA Network

Upregulated YTHDF1 associates with tumor immune microenvironment in head and neck squamous cell carcinomas

YTHDF2/m6A/NF‐κB axis controls anti‐tumor immunity by regulating intratumoral Tregs

m6A reader YTHDF2 orchestrates CD8+ T cell infiltration to promote pancreatic cancer progression and predicts clinical outcome

YTHDF1 Regulates Tumorigenicity and Cancer Stem Cell-Like Activity in Human Colorectal Carcinoma

Targeting M6a Reader YTHDF1 Augments Antitumour Immunity and Boosts Anti-Pd-1 Efficacy in Colorectal Cancer

YTHDF1 loss in dendritic cells potentiates radiation-induced antitumor immunity via STING-dependent type I IFN production

YTHDF2 is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD‐L1/VEGFA Axis

YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment

YTHDF2 Is a Therapeutic Target for HCC by Suppressing Immune Evasion and Angiogenesis Through ETV5/PD-L1/VEGFA Axis.

YTHDF1 Is a Potential Pan-Cancer Biomarker for Prognosis and Immunotherapy

YTHDF2 inhibition potentiates radiotherapy antitumor efficacy

IDDF2024-ABS-0386 Targeting M6a Reader YTHDF1 Enhances Antitumour Immunity and Potentiates Anti-Pd-l1 Efficacy in Intrahepatic Cholangiocarcinoma

YTHDF1 Aggravates the Progression of Cervical Cancer Through m(6)A-Mediated Up-Regulation of RANBP2